Inclusion Criteria:

- Patients are required to have pathologically confirmed adenocarcinoma or squamous
cell carcinoma of the esophagus, gastroesophageal junction, or stomach.

- Patients may have mediastinal, celiac adenopathy, peri-portal and regional gastric
lymphadenopathy.

- There must be no evidence of distant organ metastases.

- No prior radiation for gastric or esophageal cancer.

- Patients must be > 18 years of age, and nonpregnant

- Patients must have an ANC > 1,500/ul, platelets > 100,000/ul, creatinine < 2 x upper
limit normal (ULN) and bilirubin < 1.5 x ULN, and AST < 3 x ULN.

- ECOG performance status 0-2.

- Patients must not have significant infection or other coexistent medical condition
that would preclude protocol therapy.

- Female patients, must either be not of child bearing potential or have a negative
pregnancy test within 7 days of starting study treatment. Patients are considered not
of child bearing potential if they are surgically sterile (they have undergone a
hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
postmenopausal. Pregnant or lactating females are not eligible.

- All patients must sign informed consent

Exclusion Criteria:

Any of the following criteria will make the patient ineligible to participate in this
study:

- Acute hepatitis or AIDS.

- Active or uncontrolled infection.

- Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension,
unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled
congestive heart failure, and cardiomyopathy with decreased ejection fraction.

- Prior therapy which specifically and directly targets the EGFR pathway.

- Prior severe infusion reaction to a monoclonal antibody.

- Any concurrent chemotherapy not indicated in the study protocol or any other
investigational agent(s).